05:23 PM EST, 01/15/2025 (MT Newswires) -- Silexion Therapeutics ( SLXN ) was 74% higher in Wednesday's after-hours session, after it disclosed preclinical data demonstrated the synergistic efficacy of its SIL-204 candidate to treat certain form of pancreatic cancer.

The data show that SIL-204 worked well in combination with the primary components of two chemotherapies, 5-fluorouracil and irinotecan, in human cell lines containing pancreatic cancer with KRAS G12D mutations, the most common form of the disease. SIL-204 also showed synergistic activity with gemcitabine, another chemotherapeutic agent, Silexion said.

The company currently is preparing SIL-204 for upcoming clinical trials, with toxicology studies set to begin within a few months and phase 2/3 testing planned for H1 2026, beginning with locally advanced pancreatic cancer.